BPC October 03 update

​Arbutus ABUS discontinues early-stage hepatitis B trial - shares fall 24% after hours

Price and Volume Movers

Arbutus Biopharma Corporation (Nasdaq: ABUS) shares are trading after hours down 24% to $1.08 on news it will discontinue the development of AB-506 for the treatment of chronic hepatitis B. The decision follows two cases of acute hepatitis in a Phase 1a clinical trial in healthy volunteers.

PDS Biotechnology Corporation (Nasdaq: PDSB) shares closed up 31% to $3.94. The company announced a modification of the clinical trial collaboration agreement with a subsidiary of Merck to evaluate PDS0101, with Merck's Keytruda. The planned Phase 2 clinical trial will now evaluate the efficacy and safety of the combination as a first-line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection and is expected to be initiated in 1Q 2020.

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the FDA approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF), to reduce the risk of sexually acquired HIV-1 infection.

Tocagen Inc. (Nasdaq: TOCA) announced it will reduce its workforce by approximately 65%. Shares closed up 20% to $0.70.

Mesoblast Limited (Nasdaq: MESO) announced a placement of 37.5m shares priced at A$2 per share for a total raise of A$75m. This placement will result in the issue of 37.5 million new fully-paid ordinary shares at a price of A$2.00 per share.

Heron Therapeutics, Inc. (NASDAQ: HRTX) announced after hours it intends to offer and sell shares of its common stock in an underwritten registered public offering. Shares are trading down 7% to $17.97.

Ovid Therapeutics Inc. (Nasdaq: OVID) shares are trading down 14% to $2.81 after hours following news it also intends to offer and sell shares of its common stock and preferred stock in two public offerings.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Catalyst Biosciences, Inc. (CBIO): $6.18; +25%.

Sorrento Therapeutics, Inc. (SRNE): $2.32; +19%.

Endo International plc (ENDP): $3.86; +13%.

TCR2 Therapeutics Inc. (TCRR): $15.74; +12%.

BioLineRx Ltd. (BLRX): $2.97; +12%.


Enlivex Therapeutics Ltd. (ENLV): $11.18; -44%.

Jaguar Health, Inc. (JAGX): $1.04; -21%.

Neuralstem, Inc. (CUR): $1.45; -9%.

Adaptimmune Therapeutics plc (ADAP): $1.28; -9%.

Paratek Pharmaceuticals, Inc. (PRTK): $3.84; -8%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABUS – Arbutus Biopharma Corporation
Hepatitis B (HBV)

Phase 1 Development to be discontinued - noted October 3, 2019.
$184.8 million

APVO – Aptevo Therapeutics Inc.
Healthy volunteers

Phase 1 Development terminated - noted October 3, 2019.
$19.5 million

CBIO – Catalyst Biosciences Inc.
Dalcinonacog alfa – DalcA
Hemophilia B

Phase 2b Phase 2b final data due 2Q 2020.
$100.3 million

CRVS – Corvus Pharmaceuticals Inc.
Solid tumors

Phase 1b Phase 1/1b updated at SITC November 8, 2019 noted tumor regression in 4/9 patients receiving 6 mg/kg or higher.
$106.2 million

GILD – Gilead Sciences Inc.
F/TAF (Descovy)
Pre-exposure prophylaxis

Approved FDA Approval announced October 3, 2019.
$87.6 billion

JAGX – Jaguar Health Inc.
Mytesi (crofelemer) HALT-D
Cancer related diarrhea (CRD)

Phase 2 Phase 2 trial to enrol through to completion - November 14, 2019.
$10.1 million

KZR – Kezar Life Sciences Inc.
Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP)

Phase 2 Phase 2 interim analysis 4Q 2020 with final data due mid-2021.
$167.2 million

KZR – Kezar Life Sciences Inc.
Dermatomyositis and polymyositis

Phase 2 Phase 2 data due 2H 2021.
$167.2 million

MEIP – MEI Pharma Inc.
Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma

Phase 2 Phase 2 enrolment to be completed summer of 2020.
$204.6 million

MIST – Milestone Pharmaceuticals Inc.
Etripamil - NODE-303
Paroxysmal supraventricular tachycardia (PSVT)

Phase 3 Phase 3 open label commencement of dosing announced October 3, 2019.
$465.4 million

NGM – NGM Biopharmaceuticals Inc.
Aldafermin (NGM282)
Non-alcoholic steatohepatitis (NASH)

Phase 2 Phase 2 preliminary top-line results from the 24-week cohort (Cohort 4) met primary endpoint - February 24, 2020.
$1.2 billion

PDSB – PDS Biotechnology Corporation
Head and neck cancer / human papillomavirus-16 (HPV16) infection

Phase 2 Phase 2 trial planned for 1Q 2020 with interim data due 2Q 2021.
$17.1 million

SIGA – SIGA Technologies Inc.

NDA Filing NDA filing due 2020.
$405 million

SPRO – Spero Therapeutics Inc.
Complicated urinary tract infections (cUTI)

Phase 3 Phase 3 data due 3Q 2020.
$184 million